BARBALISCIA, SILVIA
BARBALISCIA, SILVIA
Dipartimento di Medicina Sperimentale
Characteristics and prevalence of HCV NS3, NS5A and NS5B resistance associated substitutions in HCV infected patients naive and treated with direct acting antivirals in Italy
2019-01-01 Barbaliscia, S
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
2018-01-01 Di Maio, Vc; Cento, V; Aragri, M; Paolucci, S; Pollicino, T; Coppola, N; Bruzzone, B; Ghisetti, V; Zazzi, M; Brunetto, M; Bertoli, A; Barbaliscia, S; Galli, S; Gennari, W; Baldanti, F; Raimondo, G; Perno, Cf; Ceccherini-Silberstein, F
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b
2021-01-01 Alkhatib, M; DI MAIO, Vc; De Murtas, V; Polilli, E; Milana, M; Teti, E; Fiorentino, G; Calvaruso, V; Barbaliscia, S; Bertoli, A; Scutari, R; Carioti, L; Cento, V; Santoro, M; Orro, A; Maida, I; Lenci, I; Sarmati, L; Craxì, A; Pasquazzi, C; Parruti, G; Babudieri, S; Milanesi, L; Andreoni, M; Angelico, M; Perno, C; Ceccherini-Silberstein, F; Svicher, V; Salpini, R
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study
2021-07-19 Scutari, R; Costabile, V; Galli, L; Bellocchi, Mc; Carioti, L; Barbaliscia, S; Poli, A; Galli, A; Perno, Cf; Santoro, M; Castagna, A; Ceccherini Silberstein, F; Alteri, C; Spagnuolo, V
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients
2019-01-01 Bellocchi, Mc; Aragri, M; Carioti, L; Fabeni, L; Pipitone, Rm; Brancaccio, G; Sorbo, Mc; Barbaliscia, S; Di Maio, Vc; Bronte, F; Grimaudo, S; Mazzucco, W; Frigeri, F; Cantone, M; Pinto, A; Perno, Cf; Craxì, A; Gaeta, Gb; Di Marco, V; Ceccherini-Silberstein, F
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study
2017-09-18 Cento, V; Aragri, M; Teti, E; Polilli, E; Bertoli, A; Foroghi, L; Barbaliscia, S; DI MAIO, Vc; Pieri, A; Pace Palitti, V; Sarmati, L; Parruti, G; Andreoni, M; Perno, Cf; CECCHERINI SILBERSTEIN, F
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019
2021-06-01 Rossetti, B; Paglicci, L; Di Maio, Vc; Cassol, C; Barbaliscia, S; Paolucci, S; Bruzzone, B; Coppola, N; Montagnani, F; Micheli, V; Monno, L; Zanelli, G; Santantonio, T; Cuomo, N; Caudai, C; Zazzi, M; Ceccherini-Silberstein, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C
2021-08-04 DI MAIO, Vc; Barbaliscia, S; Teti, E; Fiorentino, G; Milana, M; Paolucci, S; Pollicino, T; Morsica, G; Starace, M; Bruzzone, B; Gennari, W; Micheli, V; Yu La Rosa, K; Foroghi, L; Calvaruso, V; Lenci, I; Polilli, E; Babudieri, S; Aghemo, A; Raimondo, G; Sarmati, L; Coppola, N; Pasquazzi, C; Baldanti, F; Parruti, G; Perno, C; Angelico, M; Craxì, A; Andreoni, M; Ceccherini-Silberstein, F; Virology Italian Resistance Network Group (Vironet C), H
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-gen-2019 | Characteristics and prevalence of HCV NS3, NS5A and NS5B resistance associated substitutions in HCV infected patients naive and treated with direct acting antivirals in Italy | Barbaliscia, S | Tesi di dottorato | |
| 1-gen-2018 | Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? | Di Maio, Vc; Cento, V; Aragri, M; Paolucci, S; Pollicino, T; Coppola, N; Bruzzone, B; Ghisetti, V; Zazzi, M; Brunetto, M; Bertoli, A; Barbaliscia, S; Galli, S; Gennari, W; Baldanti, F; Raimondo, G; Perno, Cf; Ceccherini-Silberstein, F | Articolo su rivista | |
| 1-gen-2021 | Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b | Alkhatib, M; DI MAIO, Vc; De Murtas, V; Polilli, E; Milana, M; Teti, E; Fiorentino, G; Calvaruso, V; Barbaliscia, S; Bertoli, A; Scutari, R; Carioti, L; Cento, V; Santoro, M; Orro, A; Maida, I; Lenci, I; Sarmati, L; Craxì, A; Pasquazzi, C; Parruti, G; Babudieri, S; Milanesi, L; Andreoni, M; Angelico, M; Perno, C; Ceccherini-Silberstein, F; Svicher, V; Salpini, R | Articolo su rivista | |
| 19-lug-2021 | Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study | Scutari, R; Costabile, V; Galli, L; Bellocchi, Mc; Carioti, L; Barbaliscia, S; Poli, A; Galli, A; Perno, Cf; Santoro, M; Castagna, A; Ceccherini Silberstein, F; Alteri, C; Spagnuolo, V | Articolo su rivista | |
| 1-gen-2019 | NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients | Bellocchi, Mc; Aragri, M; Carioti, L; Fabeni, L; Pipitone, Rm; Brancaccio, G; Sorbo, Mc; Barbaliscia, S; Di Maio, Vc; Bronte, F; Grimaudo, S; Mazzucco, W; Frigeri, F; Cantone, M; Pinto, A; Perno, Cf; Craxì, A; Gaeta, Gb; Di Marco, V; Ceccherini-Silberstein, F | Articolo su rivista | |
| 18-set-2017 | Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study | Cento, V; Aragri, M; Teti, E; Polilli, E; Bertoli, A; Foroghi, L; Barbaliscia, S; DI MAIO, Vc; Pieri, A; Pace Palitti, V; Sarmati, L; Parruti, G; Andreoni, M; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-giu-2021 | Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 | Rossetti, B; Paglicci, L; Di Maio, Vc; Cassol, C; Barbaliscia, S; Paolucci, S; Bruzzone, B; Coppola, N; Montagnani, F; Micheli, V; Monno, L; Zanelli, G; Santantonio, T; Cuomo, N; Caudai, C; Zazzi, M; Ceccherini-Silberstein, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C | Articolo su rivista | |
| 4-ago-2021 | Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C | DI MAIO, Vc; Barbaliscia, S; Teti, E; Fiorentino, G; Milana, M; Paolucci, S; Pollicino, T; Morsica, G; Starace, M; Bruzzone, B; Gennari, W; Micheli, V; Yu La Rosa, K; Foroghi, L; Calvaruso, V; Lenci, I; Polilli, E; Babudieri, S; Aghemo, A; Raimondo, G; Sarmati, L; Coppola, N; Pasquazzi, C; Baldanti, F; Parruti, G; Perno, C; Angelico, M; Craxì, A; Andreoni, M; Ceccherini-Silberstein, F; Virology Italian Resistance Network Group (Vironet C), H | Articolo su rivista |